Skip to main content
OpenTrials
Completed

NCT Number: NCT02154516

Pilot Study Evaluating the Safety and Efficacy of a New Hard-on-Hard Total Hip Replacement System

The purpose of this study is to assess the early and long term safety and efficacy of the hard-on-hard total hip replacement system (R3 ODH-ODH utilization) in patients with non-inflammatory arthritis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Entabeni Hospital, Durban, South Africa

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • At least 21 years old
  • Skeletally mature
  • Requires primary, unilateral total hip arthroplasty due to degenerative join disease
  • Preoperative Harris Hip Score of less than or equal to 70
  • Meets an acceptable preoperative medical clearance and is free or treated for conditions that would pose excessive operative risk
  • Given consent to participate in the study
  • Able to understand the purpose of the study, his/her role, and is available for follow-up

10 year extension:

  • Subject has completed the 2 year primary study
  • Subject has signed an Independent Ethics Committee (IEC) approved Informed Consent Form agreeing to participate in the extension study after the nature, scope and possible consequences of the study have been explained in an understandable form
  • Subject is able to fully understand the purpose of the study, his/her role as a participant in the study, and plans to be available through ten years post-operative follow-up

Exclusion criteria

  • Diagnosis with high risk of Total Hip Arthroplasty (THA) failure
  • Requires bilateral THA
  • Requires revision of a prior hip replacement
  • Active infection or sepsis
  • History of local hip infection
  • Known metastatic or neoplastic disease
  • Conditions that may interfere with THA survival or outcomes
  • Need for structural bone grafts to support the implant
  • Contralateral lower extremity condition
  • Has other joint replacements or plans for other joint replacements within 2 years
  • Systemic steroid therapy within 3 months prior to surgery
  • Life expectancy less than 2 years
  • Intra-articular therapy within 6 months of enrollment
  • Female of child-bearing age not using contraception
  • Inadequate bone stock to support the device
  • Moderate to severe renal insufficiency
  • Emotional or neurological condition that would pre-empt ability or willingness to participate in the study
  • BMI >40
  • Above the knee amputation of the contralateral or ipsilateral leg
  • Known allergies to the components of the devices
  • Entered into another investigational study
  • Is a prisoner

10 year extension:

  • In the opinion of the surgeon, the subject's health, safety or well-being may be compromised or harmed by continuation in the extension phase or participation may not be in the subject's best interests.

Treatment and study plan

ODH Hip System

Device

Other names: Total Hip Replacement, THR, Total Hip Arthroplasty, THA

Primary outcomes

  1. Number of Participants With Device-Related Revisions

    Time frame: Postoperatively through 10 years

    Device related revisions reported by the number of participants with a revision required (Yes/No).

  2. Metal Ion Concentration in Whole Blood

    Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operatively.

    For both investigational (i.e., Investigational Hard-on-Hard Total Hip Replacement Device) and control (i.e., Control Total Hip Replacement Device) participants, metal ion concentration in whole blood were measured for Cobalt (Co), Chromium (Cr), Nickel (Ni), Titanium (Ti), Zirconium (Zr), Niobium (Nb), Molybdenum (Mo), Vanadium (V) and Aluminum (Al) at each indicated time frame.

Secondary outcomes

  1. Harris Hip Score (HHS) - Investigational Hard-on-Hard Total Hip Replacement Device Only

    Time frame: Preoperatively, 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operatively.

    The Harris Hip Score (HHS), which ranges from 0 (worst) to 100 (best), considers information on pain, function, and range of motion. HHS was measured for Investigational Hard-on-Hard Total Hip Replacement Device only.

  2. Hip Disability and Osteoarthritis Outcome Scores (HOOS)

    Time frame: Preoperatively, 3 months, 6 months, 1 year, 2 years, 5 years, 7 years, 10 years

    The Hip Disability and Osteoarthritis Outcome Scores (HOOS) was measured for Investigational Hard-on-Hard Total Hip Replacement Device only and included 40 items with five responses from five subcategories of Pain, Symptoms and Stiffness, Activities of Daily Living, Function in Sports and Recreational Activities, and Quality of Life to produce a total HOOS. The total HOOS scale ranged from 0 to 100, with 0 indicating the worst possible score and 100 indicating the best possible score.

  3. Radiographic Measures: Radiolucencies

    Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operative

    Radiolucencies determined by number of participants with occurrence of radiolucent lines and osteolysis (Yes/No)

  4. Radiographic Measures: Heterotopic Ossification

    Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operative

    Occurrence of Heterotopic Ossification in participants (Yes/No)

  5. Radiographic Measures: Subsidence

    Time frame: 3 months, 6 months, 1 year, 2 years, 5 years, 7 years and 10 years post-operative

    Occurrence of Subsidence in Investigational Hard-on-Hard Total Hip Replacement Device participants (Yes/No) categorized by:

    • Acetabular Cup Subsidence
    • Stem Subsidence
    • Evidence of cortical thickening
    • Acetabular component fail
    • Femoral component fail
    • Other
  6. Health Economic Outcomes: Surgical Blood Loss

    Time frame: Intra-operative, up to 50 minutes

    Blood loss during surgery measured in milliliters (ml) of blood

  7. Health Economic Outcomes: Length of Hospital Stay

    Time frame: Hospital admission to discharge

    Length of stay measured by number of days spent in hospital

  8. Health Economic Outcomes: Operative Time

    Time frame: Intra-operative

    Operative time in minutes from first incision into skin to time when last suture is applied for the Investigational Hard-on-Hard Total Hip Replacement Device group only

  9. Health Economic Outcomes: Re-Hospitalizations

    Time frame: Up to 10 years

    Re-hospitalizations measured by the number of re-admissions to hospital

Sponsors and collaborators

Lead sponsor

Smith & Nephew, Inc.

Industry

Registry information

Official study title

A Consecutive Series Pilot Study Evaluating the Safety and Effectiveness of a New Hard-on-Hard Total Hip Replacement System in Patients With Non-inflammatory Arthritis With a Standard THA Metal Ion Control Group

Important dates

Study start
2011
Primary completion
2022
Study completion
2022
First posted
Jun 3, 2014
Registry last updated
Dec 6, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.